Archimedes is a European specialty pharmaceutical company with an established commercial organisation in the UK, France and Germany and a portfolio of products marketed to specialist prescribers. Archimedes' products include Gliadel, for high grade glioma; Zomorph, an oral sustained release morphine product for cancer pain; Nozinan, a neuroleptic with anti-emetic properties, particularly suited to treat nausea and vomiting in advanced cancer patients; and Pabrinex, a high potency formulation of vitamins B and C for alcoholics experiencing acute withdrawal. Archimedes' strategy is to grow its commercial presence organically and through the acquisition of pharmaceutical companies or marketed brands in Europe and through partnering or licensing of European rights to new specialist prescribed products. In parallel, Archimedes is developing a robust pipeline of innovative near term products to support its commercial organisation. Its lead product, NasalFent®, intranasal fentanyl for rapid relief of breakthrough cancer pain, has successfully completed Phase II clinical trials and could be ready for launch in 2009. To provide further impetus and sales growth for the company in the medium term, Archimedes has an established development organisation with proprietary technologies for nasal drug delivery and a number of products in development.
